Grifols (GRFS) Short-term Investments (2010 - 2025)
Grifols (GRFS) reported Short-term Investments of $41.9 million for Q4 2025, up 553.59% on a YoY basis from $6.4 million in Q4 2024, and up 553.59% quarter-over-quarter from $6.4 million in Q4 2024.
Grifols (GRFS) Short-term Investments (2010 - 2025) Analysis & Trends
Grifols has reported Short-term Investments for 16 years, with the latest figure at $41.9 million in Q4 2025.
- For the quarter ending Q4 2025, Short-term Investments rose 553.59% year-over-year to $41.9 million; the trailing twelve-month figure through Dec 2025 stood at $41.9 million (up 553.59% YoY), and the FY2025 full-year result was $41.9 million, up 553.59% from the prior year.
- Short-term Investments for Q4 2025 stood at $41.9 million, up from $6.4 million in the prior quarter.
- The five-year high for Short-term Investments was $2.3 billion in Q4 2021, with the low at $6.4 million in Q4 2024.
- Historically, Short-term Investments has averaged $488.0 million across 5 years, with a median of $41.9 million in 2025.
- Annual changes were most pronounced in 2022 — Short-term Investments slumped 98.08% — and 2025, when it soared 553.59%.
- Grifols' Short-term Investments stood at $2.3 billion in 2021, then tumbled by 98.08% to $44.5 million in 2022, then tumbled by 42.89% to $25.4 million in 2023, then tumbled by 74.8% to $6.4 million in 2024, then surged by 553.59% to $41.9 million in 2025.
- The last three Short-term Investments figures came in at $41.9 million (Q4 2025), $6.4 million (Q4 2024), and $25.4 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41.91 Mn |
| Dec 31, 2024 | 6.41 Mn |
| Dec 31, 2023 | 25.44 Mn |
| Dec 31, 2022 | 44.55 Mn |
| Dec 31, 2021 | 2.32 Bn |
| Sep 30, 2020 | 14.35 Mn |
| Mar 31, 2020 | 14.39 Mn |
| Dec 31, 2019 | -21.53 Mn |
| Sep 30, 2019 | 3.08 Mn |
| Mar 31, 2019 | 202.58 Mn |
| Dec 31, 2018 | 22.75 Mn |
| Sep 30, 2018 | 59.78 Mn |
| Jun 30, 2018 | -16.25 Mn |
| Mar 31, 2018 | 12.92 Mn |
| Dec 31, 2017 | 12.64 Mn |
| Jun 30, 2017 | 589,358.44 |
| Dec 31, 2016 | 2.79 Mn |
| Sep 30, 2016 | 3.24 Mn |
| Jun 30, 2016 | 9.07 Mn |
| Dec 31, 2015 | 1.42 Mn |